Why Wall Street Is Backing These 3 Comeback Stocks

The article identifies The Trade Desk (TTD), Summit Therapeutics (SMMT), and Sprouts Farmers Market (SFM) as high-risk, high-reward comeback opportunities despite recent stock declines. The Trade Desk, down over 54% YTD due to an EPS miss and competition, is supported by robust 19% YOY revenue growth and platform enhancements, with analysts projecting a ~58% upside. Summit Therapeutics, a clinical-stage biotech, faces cash runway issues but has a promising drug pipeline, including an expanding Ivonescimab phase III trial, leading to a ~60% analyst-projected upside. Sprouts Farmers Market, down ~20% YTD, reported strong Q3 results with 17% YOY sales growth and share repurchases, prompting analysts to forecast a ~51% upside.

Analysis

The Trade Desk (TTD), Summit Therapeutics (SMMT), and Sprouts Farmers Market (SFM) are presented as high-risk, high-reward comeback opportunities, each experiencing recent stock declines. TTD is down over 54% year-to-date following an EPS miss and increased competition, while SMMT has fallen nearly 20% in six months due to cash runway concerns and potential dilution. SFM shares are also down approximately 20% YTD, impacted by broader inflation and consumer sentiment.

Despite these headwinds, each company exhibits specific strengths and analyst optimism. The Trade Desk reported robust 19% year-over-year revenue growth and has launched platform enhancements like Deal Desk, with 21 out of 37 analysts rating it a Buy and a consensus price target indicating 58% upside. Summit Therapeutics, a clinical-stage biotech, boasts a promising pipeline including Ivonescimab, with a biologics license application planned this quarter and 12 out of 18 analysts rating it a Buy, projecting 60% upside.

Sprouts Farmers Market demonstrated strong Q3 earnings, beating top and bottom-line estimates with 17% YOY sales growth and management raising full-year forecasts. The company utilized over $400 million in operating cash flow for shareholder incentives, including $292 million in share repurchases, and 10 out of 15 analysts rate SFM a Buy, forecasting 51% upside. The common thread across these firms is significant analyst optimism despite current challenges, suggesting a potential turnaround for risk-tolerant investors.

Key Decisions for Investors

• Investors should monitor The Trade Desk's competitive response and the adoption of its platform enhancements, particularly given its significant YTD decline and analyst-projected upside.
• For Summit Therapeutics, closely track the progress of its Ivonescimab BLA submission and Phase III expansion, while carefully assessing its cash runway and potential shareholder dilution from future financing.
• Consider Sprouts Farmers Market's ability to sustain its strong sales growth and leverage its focus on affluent customers to mitigate inflation, alongside its ongoing capital return initiatives.
• Recognize that all three companies represent high-risk, high-reward scenarios, necessitating a high degree of risk tolerance and continuous monitoring of fundamental developments.